Welcome to our dedicated page for Adaptimmune Therapeutics Plc news (Ticker: ADAPY), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics Plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adaptimmune Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adaptimmune Therapeutics Plc's position in the market.
Adaptimmune (OTC Pink: ADAPY) announced Board and executive changes effective November 14, 2025, including the appointment of Chris Hill as CEO while he continues as CFO and Director, and Lawrence Alleva as Chairman.
The company confirmed the voluntary delisting of ADSs from Nasdaq on October 28, 2025 and initiated deregistration under Section 12(b) with Form 25 and Form 15 filings; deregistration is expected around January 26, 2026. Adaptimmune said a transaction with US WorldMeds closed on July 31, 2025 to keep TECELRA available while the company focuses on maximizing value from remaining programs including PRAME and CD70.
FAQ
What is the current stock price of Adaptimmune Therapeutics Plc (ADAPY)?
